[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545055":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":44,"centralContacts":48,"locations":55,"responsibleParty":73,"collaborators":53,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":53,"enrollmentInfo":85,"targetDuration":53,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":53,"overallStatus":58,"whyStopped":53,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm One, Magnesium Sulfate 2g","EXPERIMENTAL","Study drug (Magnesium Sulfate 2 gram\u002F50ml 0.9% NaCl)",[13],"Drug: Magnesium Sulfate 2 G",{"label":15,"type":10,"description":16,"interventionNames":17},"Experimental Arm Two, Magnesium Sulfate 4g","Magnesium Sulfate 4g\u002F50ml 0.9% NaCl",[18],"Drug: Magnesium Sulfate 4 G",{"label":20,"type":21,"description":22,"interventionNames":23},"Control Arm, normal saline","PLACEBO_COMPARATOR","50ml 0.9% NaCl",[24],"Drug: Saline",[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Magnesium Sulfate 2 G","Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)",[9],[32],"Magnesium Sulfate 2 gram\u002F50ml 0.9% NaCl",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Magnesium Sulfate 4 G","Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)",[15],[16],{"type":27,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Saline","The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.",[20],[43],"Control (50ml 0.9% NaCl)",[45],{"name":46,"affiliation":5,"role":47},"Travis Hase, MD","PRINCIPAL_INVESTIGATOR",[49],{"name":50,"role":51,"phone":52,"phoneExt":53,"email":54},"Marc McDowell, PharmD","CONTACT","(708) 684-1078",null,"marc.mcdowell@aah.org",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Advocate Christ Medical Center Emergency Department (ACMC ED)","RECRUITING","Oak Lawn","Illinois","60453","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-87.75811,41.71087,{"lat":68,"lon":67},[71],{"name":50,"role":51,"phone":72,"phoneExt":53,"email":54},"708-684-6230",{"type":74,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR","100545055","phase-3-comparing-magnesium-2g-versus-4g-versus-placebo-in-the-incidence-of-treating-aff-rvr-100545055",false,"NCT06376916","Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR","Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR","ATRIUM","Inclusion Criteria:\n\n* Age \\> 18 years or older\n* Able to provide informed consent\n* Primary diagnosis AFF RVR greater than or equal to 120 bpm\n* Diltiazem as rate control agent\n* English speaking\n\nExclusion Criteria:\n\n* Hemodynamically unstable patients (SBP \\\u003C90, MAP \\\u003C65)\n* Impaired consciousness\n* End stage renal disease on hemodialysis or peritoneal dialysis\n* Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and\u002For additional imaging\n* Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis\n* Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response\n* Acute myocardial infarction\n* Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)\n* Contraindications to magnesium sulfate (including myasthenia gravis)\n* Allergy or sensitivity to any study drugs\n* Previously enrolled in this trial during a different patient encounter\n* Withdrew from study","ALL","18 Years",{"count":86,"type":87},153,"ESTIMATED","INTERVENTIONAL",[90],"PHASE3","The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.",[93,94,95],"Tachycardia Atrial","Atrial Fibrillation","Atrial Flutter With Rapid Ventricular Response","2025-10-25",{"date":98,"type":99},"2025-10-28","ACTUAL",{"date":101,"type":99},"2024-10-07",{"date":103,"type":87},"2026-12",{"name":5,"class":6},1]